 | • レポートコード：MRC2-11QY11352 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、94ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はクラミジア感染症診断・治療のグローバル市場について調査・分析したレポートです。種類別（核酸増幅検査（NAAT）、直接蛍光検査、マクロライド系抗生物質、キノロン系抗生物質、スルホンアミド系抗生物質、テトラサイクリン系抗生物質、アミノペニシリン系抗生物質）市場規模、用途別（病院、専門クリニック、診断センター治療、病院薬局、ドラッグストア、小売薬局、オンライン薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別クラミジア感染症診断・治療の競争状況、市場シェア ・世界のクラミジア感染症診断・治療市場：種類別市場規模 2015年-2020年（核酸増幅検査（NAAT）、直接蛍光検査、マクロライド系抗生物質、キノロン系抗生物質、スルホンアミド系抗生物質、テトラサイクリン系抗生物質、アミノペニシリン系抗生物質） ・世界のクラミジア感染症診断・治療市場：種類別市場規模予測 2021年-2026年（核酸増幅検査（NAAT）、直接蛍光検査、マクロライド系抗生物質、キノロン系抗生物質、スルホンアミド系抗生物質、テトラサイクリン系抗生物質、アミノペニシリン系抗生物質） ・世界のクラミジア感染症診断・治療市場：用途別市場規模 2015年-2020年（病院、専門クリニック、診断センター治療、病院薬局、ドラッグストア、小売薬局、オンライン薬局） ・世界のクラミジア感染症診断・治療市場：用途別市場規模予測 2021年-2026年（病院、専門クリニック、診断センター治療、病院薬局、ドラッグストア、小売薬局、オンライン薬局） ・北米のクラミジア感染症診断・治療市場分析：米国、カナダ ・ヨーロッパのクラミジア感染症診断・治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのクラミジア感染症診断・治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のクラミジア感染症診断・治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのクラミジア感染症診断・治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Bio Rad、Novartis、Roche、Abbott、Danaher、BioMerieux、DiaSorin、Siemens、Thermo Fisher、Becton Dickinson ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
The chlamydia infection diagnostics and therapeutics market unveils high potential owing to the rapidly rising patient pool and vast untapped opportunities.
Market Analysis and Insights: Global Chlamydia Infection Diagnostics and Therapeutics Market
The global Chlamydia Infection Diagnostics and Therapeutics market size is projected to reach US$ 886.9 million by 2026, from US$ 856.4 million in 2020, at a CAGR of 3.3%% during 2021-2026.
Global Chlamydia Infection Diagnostics and Therapeutics Scope and Market Size
Chlamydia Infection Diagnostics and Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Chlamydia Infection Diagnostics and Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Bio Rad
Novartis
Roche
Abbott
Danaher
BioMerieux
DiaSorin
Siemens
Thermo Fisher
Becton Dickinson
Market segment by Type, the product can be split into
Nucleic Acid Amplification Tests (NAATs)
Direct Fluorescent Tests
Macrolides
Quinolones
Sulfonamides
Tetracycline
Aminopenicillins
Market segment by Application, split into
Hospitals
Specialty Clinics
Diagnostic Centers Therapeutics
Hospital Pharmacies
Drugstores
Retail Pharmacies
Online Pharmacies
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Chlamydia Infection Diagnostics and Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Chlamydia Infection Diagnostics and Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Nucleic Acid Amplification Tests (NAATs)
1.4.3 Direct Fluorescent Tests
1.4.4 Macrolides
1.4.5 Quinolones
1.4.6 Sulfonamides
1.4.7 Tetracycline
1.4.8 Aminopenicillins
1.5 Market by Application
1.5.1 Global Chlamydia Infection Diagnostics and Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Specialty Clinics
1.5.4 Diagnostic Centers Therapeutics
1.5.5 Hospital Pharmacies
1.5.6 Drugstores
1.5.7 Retail Pharmacies
1.5.8 Online Pharmacies
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Chlamydia Infection Diagnostics and Therapeutics Market Perspective (2015-2026)
2.2 Global Chlamydia Infection Diagnostics and Therapeutics Growth Trends by Regions
2.2.1 Chlamydia Infection Diagnostics and Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Chlamydia Infection Diagnostics and Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Chlamydia Infection Diagnostics and Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Chlamydia Infection Diagnostics and Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Chlamydia Infection Diagnostics and Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Chlamydia Infection Diagnostics and Therapeutics Players by Market Size
3.1.1 Global Top Chlamydia Infection Diagnostics and Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Chlamydia Infection Diagnostics and Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Chlamydia Infection Diagnostics and Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Chlamydia Infection Diagnostics and Therapeutics Market Concentration Ratio
3.2.1 Global Chlamydia Infection Diagnostics and Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Chlamydia Infection Diagnostics and Therapeutics Revenue in 2019
3.3 Chlamydia Infection Diagnostics and Therapeutics Key Players Head office and Area Served
3.4 Key Players Chlamydia Infection Diagnostics and Therapeutics Product Solution and Service
3.5 Date of Enter into Chlamydia Infection Diagnostics and Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Chlamydia Infection Diagnostics and Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Chlamydia Infection Diagnostics and Therapeutics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Chlamydia Infection Diagnostics and Therapeutics Market Size by Application (2015-2020)
5.2 Global Chlamydia Infection Diagnostics and Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Chlamydia Infection Diagnostics and Therapeutics Market Size (2015-2020)
6.2 Chlamydia Infection Diagnostics and Therapeutics Key Players in North America (2019-2020)
6.3 North America Chlamydia Infection Diagnostics and Therapeutics Market Size by Type (2015-2020)
6.4 North America Chlamydia Infection Diagnostics and Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Chlamydia Infection Diagnostics and Therapeutics Market Size (2015-2020)
7.2 Chlamydia Infection Diagnostics and Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Chlamydia Infection Diagnostics and Therapeutics Market Size by Type (2015-2020)
7.4 Europe Chlamydia Infection Diagnostics and Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China Chlamydia Infection Diagnostics and Therapeutics Market Size (2015-2020)
8.2 Chlamydia Infection Diagnostics and Therapeutics Key Players in China (2019-2020)
8.3 China Chlamydia Infection Diagnostics and Therapeutics Market Size by Type (2015-2020)
8.4 China Chlamydia Infection Diagnostics and Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Chlamydia Infection Diagnostics and Therapeutics Market Size (2015-2020)
9.2 Chlamydia Infection Diagnostics and Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Chlamydia Infection Diagnostics and Therapeutics Market Size by Type (2015-2020)
9.4 Japan Chlamydia Infection Diagnostics and Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Chlamydia Infection Diagnostics and Therapeutics Market Size (2015-2020)
10.2 Chlamydia Infection Diagnostics and Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Chlamydia Infection Diagnostics and Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Chlamydia Infection Diagnostics and Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India Chlamydia Infection Diagnostics and Therapeutics Market Size (2015-2020)
11.2 Chlamydia Infection Diagnostics and Therapeutics Key Players in India (2019-2020)
11.3 India Chlamydia Infection Diagnostics and Therapeutics Market Size by Type (2015-2020)
11.4 India Chlamydia Infection Diagnostics and Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Chlamydia Infection Diagnostics and Therapeutics Market Size (2015-2020)
12.2 Chlamydia Infection Diagnostics and Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Chlamydia Infection Diagnostics and Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Chlamydia Infection Diagnostics and Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Bio Rad
13.1.1 Bio Rad Company Details
13.1.2 Bio Rad Business Overview
13.1.3 Bio Rad Chlamydia Infection Diagnostics and Therapeutics Introduction
13.1.4 Bio Rad Revenue in Chlamydia Infection Diagnostics and Therapeutics Business (2015-2020))
13.1.5 Bio Rad Recent Development
13.2 Novartis
13.2.1 Novartis Company Details
13.2.2 Novartis Business Overview
13.2.3 Novartis Chlamydia Infection Diagnostics and Therapeutics Introduction
13.2.4 Novartis Revenue in Chlamydia Infection Diagnostics and Therapeutics Business (2015-2020)
13.2.5 Novartis Recent Development
13.3 Roche
13.3.1 Roche Company Details
13.3.2 Roche Business Overview
13.3.3 Roche Chlamydia Infection Diagnostics and Therapeutics Introduction
13.3.4 Roche Revenue in Chlamydia Infection Diagnostics and Therapeutics Business (2015-2020)
13.3.5 Roche Recent Development
13.4 Abbott
13.4.1 Abbott Company Details
13.4.2 Abbott Business Overview
13.4.3 Abbott Chlamydia Infection Diagnostics and Therapeutics Introduction
13.4.4 Abbott Revenue in Chlamydia Infection Diagnostics and Therapeutics Business (2015-2020)
13.4.5 Abbott Recent Development
13.5 Danaher
13.5.1 Danaher Company Details
13.5.2 Danaher Business Overview
13.5.3 Danaher Chlamydia Infection Diagnostics and Therapeutics Introduction
13.5.4 Danaher Revenue in Chlamydia Infection Diagnostics and Therapeutics Business (2015-2020)
13.5.5 Danaher Recent Development
13.6 BioMerieux
13.6.1 BioMerieux Company Details
13.6.2 BioMerieux Business Overview
13.6.3 BioMerieux Chlamydia Infection Diagnostics and Therapeutics Introduction
13.6.4 BioMerieux Revenue in Chlamydia Infection Diagnostics and Therapeutics Business (2015-2020)
13.6.5 BioMerieux Recent Development
13.7 DiaSorin
13.7.1 DiaSorin Company Details
13.7.2 DiaSorin Business Overview
13.7.3 DiaSorin Chlamydia Infection Diagnostics and Therapeutics Introduction
13.7.4 DiaSorin Revenue in Chlamydia Infection Diagnostics and Therapeutics Business (2015-2020)
13.7.5 DiaSorin Recent Development
13.8 Siemens
13.8.1 Siemens Company Details
13.8.2 Siemens Business Overview
13.8.3 Siemens Chlamydia Infection Diagnostics and Therapeutics Introduction
13.8.4 Siemens Revenue in Chlamydia Infection Diagnostics and Therapeutics Business (2015-2020)
13.8.5 Siemens Recent Development
13.9 Thermo Fisher
13.9.1 Thermo Fisher Company Details
13.9.2 Thermo Fisher Business Overview
13.9.3 Thermo Fisher Chlamydia Infection Diagnostics and Therapeutics Introduction
13.9.4 Thermo Fisher Revenue in Chlamydia Infection Diagnostics and Therapeutics Business (2015-2020)
13.9.5 Thermo Fisher Recent Development
13.10 Becton Dickinson
13.10.1 Becton Dickinson Company Details
13.10.2 Becton Dickinson Business Overview
13.10.3 Becton Dickinson Chlamydia Infection Diagnostics and Therapeutics Introduction
13.10.4 Becton Dickinson Revenue in Chlamydia Infection Diagnostics and Therapeutics Business (2015-2020)
13.10.5 Becton Dickinson Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Chlamydia Infection Diagnostics and Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Chlamydia Infection Diagnostics and Therapeutics Revenue
Table 3. Ranking of Global Top Chlamydia Infection Diagnostics and Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Chlamydia Infection Diagnostics and Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Nucleic Acid Amplification Tests (NAATs)
Table 6. Key Players of Direct Fluorescent Tests
Table 7. Key Players of Macrolides
Table 8. Key Players of Quinolones
Table 9. Key Players of Sulfonamides
Table 10. Key Players of Tetracycline
Table 11. Key Players of Aminopenicillins
Table 12. Global Chlamydia Infection Diagnostics and Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 13. Global Chlamydia Infection Diagnostics and Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 14. Global Chlamydia Infection Diagnostics and Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 15. Global Chlamydia Infection Diagnostics and Therapeutics Market Share by Regions (2015-2020)
Table 16. Global Chlamydia Infection Diagnostics and Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 17. Global Chlamydia Infection Diagnostics and Therapeutics Market Share by Regions (2021-2026)
Table 18. Market Top Trends
Table 19. Key Drivers: Impact Analysis
Table 20. Key Challenges
Table 21. Chlamydia Infection Diagnostics and Therapeutics Market Growth Strategy
Table 22. Main Points Interviewed from Key Chlamydia Infection Diagnostics and Therapeutics Players
Table 23. Global Chlamydia Infection Diagnostics and Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 24. Global Chlamydia Infection Diagnostics and Therapeutics Market Share by Players (2015-2020)
Table 25. Global Top Chlamydia Infection Diagnostics and Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chlamydia Infection Diagnostics and Therapeutics as of 2019)
Table 26. Global Chlamydia Infection Diagnostics and Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Chlamydia Infection Diagnostics and Therapeutics Product Solution and Service
Table 29. Date of Enter into Chlamydia Infection Diagnostics and Therapeutics Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Chlamydia Infection Diagnostics and Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 32. Global Chlamydia Infection Diagnostics and Therapeutics Market Size Share by Type (2015-2020)
Table 33. Global Chlamydia Infection Diagnostics and Therapeutics Revenue Market Share by Type (2021-2026)
Table 34. Global Chlamydia Infection Diagnostics and Therapeutics Market Size Share by Application (2015-2020)
Table 35. Global Chlamydia Infection Diagnostics and Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 36. Global Chlamydia Infection Diagnostics and Therapeutics Market Size Share by Application (2021-2026)
Table 37. North America Key Players Chlamydia Infection Diagnostics and Therapeutics Revenue (2019-2020) (Million US$)
Table 38. North America Key Players Chlamydia Infection Diagnostics and Therapeutics Market Share (2019-2020)
Table 39. North America Chlamydia Infection Diagnostics and Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 40. North America Chlamydia Infection Diagnostics and Therapeutics Market Share by Type (2015-2020)
Table 41. North America Chlamydia Infection Diagnostics and Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 42. North America Chlamydia Infection Diagnostics and Therapeutics Market Share by Application (2015-2020)
Table 43. Europe Key Players Chlamydia Infection Diagnostics and Therapeutics Revenue (2019-2020) (Million US$)
Table 44. Europe Key Players Chlamydia Infection Diagnostics and Therapeutics Market Share (2019-2020)
Table 45. Europe Chlamydia Infection Diagnostics and Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 46. Europe Chlamydia Infection Diagnostics and Therapeutics Market Share by Type (2015-2020)
Table 47. Europe Chlamydia Infection Diagnostics and Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 48. Europe Chlamydia Infection Diagnostics and Therapeutics Market Share by Application (2015-2020)
Table 49. China Key Players Chlamydia Infection Diagnostics and Therapeutics Revenue (2019-2020) (Million US$)
Table 50. China Key Players Chlamydia Infection Diagnostics and Therapeutics Market Share (2019-2020)
Table 51. China Chlamydia Infection Diagnostics and Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 52. China Chlamydia Infection Diagnostics and Therapeutics Market Share by Type (2015-2020)
Table 53. China Chlamydia Infection Diagnostics and Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 54. China Chlamydia Infection Diagnostics and Therapeutics Market Share by Application (2015-2020)
Table 55. Japan Key Players Chlamydia Infection Diagnostics and Therapeutics Revenue (2019-2020) (Million US$)
Table 56. Japan Key Players Chlamydia Infection Diagnostics and Therapeutics Market Share (2019-2020)
Table 57. Japan Chlamydia Infection Diagnostics and Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 58. Japan Chlamydia Infection Diagnostics and Therapeutics Market Share by Type (2015-2020)
Table 59. Japan Chlamydia Infection Diagnostics and Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 60. Japan Chlamydia Infection Diagnostics and Therapeutics Market Share by Application (2015-2020)
Table 61. Southeast Asia Key Players Chlamydia Infection Diagnostics and Therapeutics Revenue (2019-2020) (Million US$)
Table 62. Southeast Asia Key Players Chlamydia Infection Diagnostics and Therapeutics Market Share (2019-2020)
Table 63. Southeast Asia Chlamydia Infection Diagnostics and Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 64. Southeast Asia Chlamydia Infection Diagnostics and Therapeutics Market Share by Type (2015-2020)
Table 65. Southeast Asia Chlamydia Infection Diagnostics and Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 66. Southeast Asia Chlamydia Infection Diagnostics and Therapeutics Market Share by Application (2015-2020)
Table 67. India Key Players Chlamydia Infection Diagnostics and Therapeutics Revenue (2019-2020) (Million US$)
Table 68. India Key Players Chlamydia Infection Diagnostics and Therapeutics Market Share (2019-2020)
Table 69. India Chlamydia Infection Diagnostics and Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 70. India Chlamydia Infection Diagnostics and Therapeutics Market Share by Type (2015-2020)
Table 71. India Chlamydia Infection Diagnostics and Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 72. India Chlamydia Infection Diagnostics and Therapeutics Market Share by Application (2015-2020)
Table 73. Central & South America Key Players Chlamydia Infection Diagnostics and Therapeutics Revenue (2019-2020) (Million US$)
Table 74. Central & South America Key Players Chlamydia Infection Diagnostics and Therapeutics Market Share (2019-2020)
Table 75. Central & South America Chlamydia Infection Diagnostics and Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 76. Central & South America Chlamydia Infection Diagnostics and Therapeutics Market Share by Type (2015-2020)
Table 77. Central & South America Chlamydia Infection Diagnostics and Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 78. Central & South America Chlamydia Infection Diagnostics and Therapeutics Market Share by Application (2015-2020)
Table 79. Bio Rad Company Details
Table 80. Bio Rad Business Overview
Table 81. Bio Rad Product
Table 82. Bio Rad Revenue in Chlamydia Infection Diagnostics and Therapeutics Business (2015-2020) (Million US$)
Table 83. Bio Rad Recent Development
Table 84. Novartis Company Details
Table 85. Novartis Business Overview
Table 86. Novartis Product
Table 87. Novartis Revenue in Chlamydia Infection Diagnostics and Therapeutics Business (2015-2020) (Million US$)
Table 88. Novartis Recent Development
Table 89. Roche Company Details
Table 90. Roche Business Overview
Table 91. Roche Product
Table 92. Roche Revenue in Chlamydia Infection Diagnostics and Therapeutics Business (2015-2020) (Million US$)
Table 93. Roche Recent Development
Table 94. Abbott Company Details
Table 95. Abbott Business Overview
Table 96. Abbott Product
Table 97. Abbott Revenue in Chlamydia Infection Diagnostics and Therapeutics Business (2015-2020) (Million US$)
Table 98. Abbott Recent Development
Table 99. Danaher Company Details
Table 100. Danaher Business Overview
Table 101. Danaher Product
Table 102. Danaher Revenue in Chlamydia Infection Diagnostics and Therapeutics Business (2015-2020) (Million US$)
Table 103. Danaher Recent Development
Table 104. BioMerieux Company Details
Table 105. BioMerieux Business Overview
Table 106. BioMerieux Product
Table 107. BioMerieux Revenue in Chlamydia Infection Diagnostics and Therapeutics Business (2015-2020) (Million US$)
Table 108. BioMerieux Recent Development
Table 109. DiaSorin Company Details
Table 110. DiaSorin Business Overview
Table 111. DiaSorin Product
Table 112. DiaSorin Revenue in Chlamydia Infection Diagnostics and Therapeutics Business (2015-2020) (Million US$)
Table 113. DiaSorin Recent Development
Table 114. Siemens Business Overview
Table 115. Siemens Product
Table 116. Siemens Company Details
Table 117. Siemens Revenue in Chlamydia Infection Diagnostics and Therapeutics Business (2015-2020) (Million US$)
Table 118. Siemens Recent Development
Table 119. Thermo Fisher Company Details
Table 120. Thermo Fisher Business Overview
Table 121. Thermo Fisher Product
Table 122. Thermo Fisher Revenue in Chlamydia Infection Diagnostics and Therapeutics Business (2015-2020) (Million US$)
Table 123. Thermo Fisher Recent Development
Table 124. Becton Dickinson Company Details
Table 125. Becton Dickinson Business Overview
Table 126. Becton Dickinson Product
Table 127. Becton Dickinson Revenue in Chlamydia Infection Diagnostics and Therapeutics Business (2015-2020) (Million US$)
Table 128. Becton Dickinson Recent Development
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Chlamydia Infection Diagnostics and Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Nucleic Acid Amplification Tests (NAATs) Features
Figure 3. Direct Fluorescent Tests Features
Figure 4. Macrolides Features
Figure 5. Quinolones Features
Figure 6. Sulfonamides Features
Figure 7. Tetracycline Features
Figure 8. Aminopenicillins Features
Figure 9. Global Chlamydia Infection Diagnostics and Therapeutics Market Share by Application: 2020 VS 2026
Figure 10. Hospitals Case Studies
Figure 11. Specialty Clinics Case Studies
Figure 12. Diagnostic Centers Therapeutics Case Studies
Figure 13. Hospital Pharmacies Case Studies
Figure 14. Drugstores Case Studies
Figure 15. Retail Pharmacies Case Studies
Figure 16. Online Pharmacies Case Studies
Figure 17. Chlamydia Infection Diagnostics and Therapeutics Report Years Considered
Figure 18. Global Chlamydia Infection Diagnostics and Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 19. Global Chlamydia Infection Diagnostics and Therapeutics Market Share by Regions: 2020 VS 2026
Figure 20. Global Chlamydia Infection Diagnostics and Therapeutics Market Share by Regions (2021-2026)
Figure 21. Porter's Five Forces Analysis
Figure 22. Global Chlamydia Infection Diagnostics and Therapeutics Market Share by Players in 2019
Figure 23. Global Top Chlamydia Infection Diagnostics and Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chlamydia Infection Diagnostics and Therapeutics as of 2019
Figure 24. The Top 10 and 5 Players Market Share by Chlamydia Infection Diagnostics and Therapeutics Revenue in 2019
Figure 25. North America Chlamydia Infection Diagnostics and Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Europe Chlamydia Infection Diagnostics and Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. China Chlamydia Infection Diagnostics and Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Japan Chlamydia Infection Diagnostics and Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. Southeast Asia Chlamydia Infection Diagnostics and Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 30. India Chlamydia Infection Diagnostics and Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 31. Central & South America Chlamydia Infection Diagnostics and Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 32. Bottom-up and Top-down Approaches for This Report
Figure 33. Data Triangulation
Figure 34. Key Executives Interviewed
クラミジア診断・治療の世界市場（～2026年） Chlamydia trachomatis is a type of sexually transmitted disease that is prevalent in population of all age group, but women are much more vulnerable to it. The Chlamydia diagnosis involves a series of test such as urine culture, The change in lifestyle especially related to sex preferences is the ma…- 菌血症検査の世界市場（～2026年） BSIs occur when any causative organism enters the bloodstream through a wound, injection, or during a surgical procedure. BSI testing is done to detect the cause of these infections. Bloodstream infections are mostly diagnosed by blood culture tests and molecular tests. Commercially available tests …
- 自己免疫疾患用体外診断（IVD）・ラボ開発検査の世界市場（～2026年） In vitro diagnostics (IVD) are tests on bodily samples like blood, tissue or urine. IVDs are used to detect diseases, conditions, or infections.LDT for autoimmune diseases are tests specially developed in laboratory testing some autoimmune diseases. The market growth is attributed to rising occurren…
- ペプチド感染症治療薬の世界市場（～2026年） Peptide therapeutics are stable, safe, tolerable, possess selective nature, and effective. Hospital pharmacies segment enjoys the highest market share by revenue thereby dominating the global market. Market Analysis and Insights: Global Peptide Based Infection Therapeutics Market The global Peptide …
- 強皮症診断・治療の世界市場（～2026年） Market Analysis and Insights: Global Scleroderma Diagnostics and Therapeutics Market The global Scleroderma Diagnostics and Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Scleroderma Diagnostics and Thera…